Pure Global
NCT04065490

Study of Photobiomodulation to Treat Dry Age-Related Macular Degeneration (LIGHTSITE III)

A Double-Masked, Randomized, Sham-Controlled, Parallel Group, Multi-Center Study to Assess the Safety and Efficacy of Photobiomodulation (PBM) in Subjects With Dry Age-Related Macular Degeneration (AMD) (LIGHTSITE III)
LumiThera, Inc.·ClinicalTrials.gov·device·Device trialNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Dry Age-related Macular Degeneration
Drug/Device/Intervention
Valeda PBM treatment
Study type
Interventional
Intervention type
device
Sponsor & location
Primary sponsor
LumiThera, Inc.
Location
Beverly Hills,Palo Alto,Altamonte Springs,Hagerstown,Cherry Hill,New York,Durham,Chambersburg,McAllen,The Woodlands,Silverdale, United States of America
Timeline & enrollment
Phase
N/A
Start date
Sep 01, 2019
End date
Jun 01, 2022
Enrollment
96 participants
Primary outcome

Best Corrected Visual Acuity

Summary

This LIGHTSITE III study is a double-masked, sham-controlled, parallel design, prospective
 multi-site study for the use of PBM as a treatment for visual impairment in subjects with dry
 AMD.

ICD-10 classifications
Peripheral retinal degenerationCorneal degenerationHereditary retinal dystrophyOptic atrophy in diseases classified elsewhereDisorders of choroid and retina
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT04065490
Type
Device Trial
About this record

Access comprehensive clinical trial information for NCT04065490 through Pure Global AI's free database. This phase not specified trial is sponsored by LumiThera, Inc. and is currently Not yet recruiting. The study focuses on Dry Age-related Macular Degeneration. Target enrollment is 96 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.